雅思阅读模拟练习一篇_雅思英语阅读

雅思阅读模拟练习一篇

　　Combretastin appears to work very quickly, often reducing the blood flow to a tumour within four to six hours after its first application. A feature in its favour is that combretastin does not appear to affect the blood supplies to other healthy organs. But, used in isolation, a small number of cancerous cells which appear able to live off normal blood supplies, appear to remain unaffected by combretastin, and radiation therapy is required to destroy these cells and remove the threat of cancer altogether.

　　Initial trials have been carried out on twenty-five patients in the USA. These have met with a remarkable measure of success. One 55-year-old man, suffering from a particularly aggressive form of thyroid cancer before treatment, has been cancer-free for two years following a course of the new drug. It is generally held that if a cancer does not return within two years of treatment, it has been cured. So far, other patients involved in the trials since then, including those with cancer of the bowel, have also remained clear of their cancers.

　　Trials in the UK have met with similar success, but have reported significant side effects, including diarrhoea and skin pain. In Britain, experts believe that the drug works best in conjunction with other therapies, including radiotherapy. The results of these combined treatments suggest that 85% of cancers could be totally eliminated, and similar trials are due to start in the USA. Dr Kate Law of the Cancer Research Campaign in London comments, We will be watching the results of these trials with interest. On the face of it, these latest trials are very encouraging.